TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9649988
Drug: PCA group
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA group received a continuous infusion of 1.5 mg h‐1 piritramide
Study: 9649988
Drug: i.m. group
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. group received 0.3 mg kg‐1 piritramide i.m. when requested by the patient
Study: 2888937
Drug: Antidepressants (imipramine)
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (imipramine)
Study: 28434056
Drug: Behavioral intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioral intervention targeting maternal alcohol use, malnutrition, and HIV, specific dosage and duration not available
Study: 22773391
Drug: Sequential portal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential portal and arterial revascularization (SPAr)
Study: 17059015
Drug: Four-step therapeutics
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-step therapeutics of Traditional Chinese Medicine (TCM)
Study: 17059015
Drug: 100mg Lamivudine
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg Lamivudine orally daily for two years (Control)
Study: 10908991
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with Meniett apparatus
Study: 8113660
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg of prostaglandin E2 in 3 ml of gel intracervically
Study: 8113660
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg prostaglandin E2 tablet intravaginally
Study: 31618456
Drug: Reduced-dose plerixafor
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose plerixafor (0.12 mg/kg) plus filgrastim (10 μg/kg/4 days)
Study: 26572609
Drug: Protein-rich nutritional
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-rich nutritional supplementation (40g of protein and 600 kcal daily for six months) and bisphosphonates (once weekly for 12 months)
Study: 26572609
Drug: Bisphosphonates alone
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonates alone (once weekly for 12 months)
Study: 26572609
Drug: Calcium (1g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1g daily) and vitamin D3 (800 IU daily)
Study: 23546559
Drug: Nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous oxide (N2O) by inhalation
Study: 23546559
Drug: Deep sedation
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep sedation (intravenous mixture of midazolam, remifentanil, and propofol)
Study: 9722274
Drug: Control (water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (water solution)
Study: 2730998
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (300 mg/kg body weight)
Study: 2730998
Drug: Placebo (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (8 g sodium chloride)
Study: 1101842
Drug: Very high
Normalized name: Very high density lipoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very high dose fluphenazine (1,200 mg/day)
Study: 1101842
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose fluphenazine
Study: 31951771
Drug: HepB control
Approvals — FDA: no, EMA: no, PMDA: no
Description: HepB control vaccine
Study: 24697345
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment combined with bladder training (n = 440)
Study: 24697345
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment alone (n = 405)
Study: 29354930
Drug: Skin needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin needle embedding therapy
Study: 18928105
Drug: Non-steroid anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroid anti-inflammatory drugs
Study: 12373475
Drug: Early surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early surfactant administration (Curosurf at a dose of 100 mg/kg as a single bolus via the endotracheal tube within 1 min after intubation)
Study: 12373475
Drug: Delayed surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed surfactant administration (during HFOV only when defined criteria were reached)
Study: 12373475
Drug: Delayed surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed surfactant administration
Study: 7760659
Drug: Cortisporin Otic
Normalized name: Cortisporin Otic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisporin Otic Suspension (COS; 0.5 mL)
Study: 2081608
Drug: Propranolol (80-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80-160 mg per day)
Study: 2081608
Drug: Acebutolol (400-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (400-800 mg per day)
Study: 29461121
Drug: Topical 3%
Normalized name: sulfur topical 3% topical soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 3% tranexamic acid combined with 1064-nm QSNYL laser
Study: 25123170
Drug: Three daily
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three daily servings of dairy products
Study: 18688814
Drug: B. macrostemi
Approvals — FDA: no, EMA: no, PMDA: no
Description: B. macrostemi plus baseline therapy
Study: 18688814
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus baseline therapy
Study: 16367880
Drug: Pioglitazone (15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (15, 30, and 45 mg)
Study: 3559982
Drug: Morphine (7.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (7.5, 15, and 30 mg)
Study: 3559982
Drug: Pentazocine (22.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine (22.5, 45, and 90 mg)
Study: 3559982
Drug: Ciramadol (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciramadol (30, 60, and 120 mg)
Study: 22298568
Drug: Oral tocotrienols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tocotrienols (200 mg mixed tocotrienols, b.i.d.)
Study: 22298568
Drug: Oral tocopherols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tocopherols (200 mg α‐tocopherol, b.i.d.)
Study: 22834565
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) therapy
Study: 18245019
Drug: Metabotropic glutamate
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Metabotropic glutamate receptor agonists
Study: 18245019
Drug: Dopamine receptor‐blocking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine receptor‐blocking drugs
Study: 15914552
Drug: R-CHOP (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP (375 mg/m2 rituximab with each chemotherapy cycle, n = 99)
Study: 15914552
Drug: CHOP (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP (no immunotherapy, n = 50)
Study: 7703929
Drug: Ampho‐B/G (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampho‐B/G (1 mg/kg)
Study: 7703929
Drug: Ampho‐B/Lipid (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampho‐B/Lipid (1 mg/kg)
Study: 7703929
Drug: AmBisome (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmBisome (3 mg/kg)
Study: 495529
Drug: Hypnotic subjects
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic subjects
Study: 29257754
Drug: rs4693075 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: rs4693075 in patients suffering SAMS (CC=36.8%, CG=48.2%, GG=15.0%)
Study: 14766438
Drug: Buspirone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone treatment
Study: 20562170
Drug: Estrogen pre-treatment
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen pre-treatment
Study: 20562170
Drug: Buspirone after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone after estrogen pre-treatment
Study: 19393480
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no anti-dyslipidemic therapy)
Study: 11219208
Drug: Intracoronary radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary radiation therapy
Study: 11219208
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (angioplasty and stenting)
Study: 15881488
Drug: Sulfonylurea plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylurea plus metformin
Study: 4558903
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of Delta(9)‐tetrahydrocannabinol and 11‐OH‐Delta(9)‐tetrahydrocannabinol
Study: 23663534
Drug: Mindfulness-based meditation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based meditation intervention (8 weekly sessions, 90 min each)
Study: 21859484
Drug: Nebulized beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized beclomethasone dipropionate (BDP) 400 μg b.i.d. plus nebulized salbutamol 2500 μg prn
Study: 21859484
Drug: Nebulized placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized placebo plus nebulized salbutamol 2500 μg prn
Study: 17317044
Drug: Early home-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early home-based intervention with monthly specific home visits between the infant ages of 5 and 9 months
Study: 11929404
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg once a day
Study: 11929404
Drug: Famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 20 mg twice a day
Study: 2916514
Drug: Theophylline (Theo-Dur
Normalized name: THEOPHYLLINE (THEO-DUR) 300MG SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (Theo-Dur tablets, 14 to 16 mg/kg per day or their usual dose, whichever was higher)
Study: 768909
Drug: acebutolol 500
Normalized name: acebutolol 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: acebutolol 500 mg
Study: 768909
Drug: bendrofluazide 5-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: bendrofluazide 5-15 mg
Study: 29127558
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone (4 mg)
Study: 28449690
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg iron as NaFeEDTA
Study: 28449690
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg iron as encapsulated ferrous fumarate
Study: 20021666
Drug: Tetrabenazine (TBZ),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrabenazine (TBZ), maximum dosage of 200 mg/day, titrated to the best individual dose over 80 weeks.
Study: 15152555
Drug: Alfetin (biological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfetin (biological preparation)
Study: 30047357
Drug: Exposure in
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure in vivo (EXP), a cognitive-behavioral treatment targeting pain-related fear
Study: 30047357
Drug: Pain-contingent physical
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain-contingent physical therapy (PPT)
Study: 27146814
Drug: Pantoprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (40 mg ID for 2 days)
Study: 27146814
Drug: Rosuvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (10 mg) alone
Study: 16260822
Drug: Internet-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive-behavioral therapy with minimal therapist contact plus participation in a discussion group
Study: 12137110
Drug: Hydrostatic anti-G
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrostatic anti-G suit (Libelle; L)
Study: 12137110
Drug: Pneumatic anti-G
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumatic anti-G ensemble (AGE-39) with full anti-G straining maneuvers (FM)
Study: 12137110
Drug: Pneumatic anti-G
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumatic anti-G ensemble (AGE-39) with reduced anti-G straining maneuvers (RM)
Study: 10594422
Drug: rocuronium (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium (20 mg)
Study: 10594422
Drug: vecuronium (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: vecuronium (4 mg)
Study: 12812862
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (synthetic estrogens)
Study: 12812862
Drug: Oral Contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Contraceptive (OC) use
Study: 45463
Drug: Lergotrile mesylate
Normalized name: Lergotrile mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lergotrile mesylate (2 mg oral)
Study: 25568388
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (posterior or anterior arthrodesis)
Study: 25568388
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (body cast or orthosis)
Study: 17073812
Drug: High-dose human
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose human ALB (albumin) therapy
Study: 8336224
Drug: Midazolam (.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (.35 mg/kg)
Study: 8336224
Drug: Diazepam (.70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (.70 mg/kg)
Study: 3534348
Drug: Dexamethasone (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (IV 16 mg 1/2 hr before and 8 mg at 1 1/2, 3 1/2, and 5 1/2 hr after cisplatin)
Study: 3534348
Drug: Metoclopramide (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (IV 2 mg/kg 1/2 hr before and 1 1/2, 3 1/2, and 5 1/2 hr after cisplatin)
Study: 3534348
Drug: Overall response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Overall response to antiemetic agents
Study: 29590698
Drug: Standardised cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised cooling and compression therapy with the Cryo/Cuff™‐system (3 × 10 min twice daily)
Study: 29590698
Drug: Conventional cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cooling therapy
Study: 26928670
Drug: Celecoxib 800
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 800 mg/day
Study: 24572997
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 mg/kg intravenously over 2 hours)
Study: 24572997
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline 5 mL/kg intravenously)
Study: 19884368
Drug: Nemonoxacin 125
Normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin 125 mg
Study: 25092690
Drug: Nemonoxacin 250
Normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin 250 mg
Study: 25092690
Drug: Nemonoxacin 500
Normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin 500 mg
Study: 25092690
Drug: Nemonoxacin 750
Normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin 750 mg
Study: 22650326
Drug: Nemonoxacin 500
Normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin 500 mg (multiple doses)
Study: 22650326
Drug: Nemonoxacin 500
Normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin 500 mg (fed conditions)
Study: 20306554
Drug: Raltegravir 200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 200, 400, or 600 mg b.i.d. plus optimized background therapy
Study: 20306554
Drug: Placebo b.i.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo b.i.d. plus optimized background therapy
Study: 18310400
Drug: Carefully selected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carefully selected pharmacological therapy
Study: 12588019
Drug: 2TU PPD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2TU PPD prepared by the Guindy laboratory (Dilution-G)
Study: 12588019
Drug: 1TU and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1TU and 2TU Dilution-G
Study: 10583708
Drug: Intravenous Mg
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Mg load with 0.1 mmol Mg-aspartate hydrochloride per kilogram bodyweight for 1 hour.
Study: 10583708
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group receiving no Mg medication.
Study: 10583708
Drug: Baseline Mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline Mg values measured by atomic absorption spectroscopy (AAS) in serum and urine.
Study: 10583708
Drug: Femur Mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femur Mg concentration measured by AAS.
Study: 10583708
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of femur Mg concentration and %Ret.
Study: 6198313
Drug: Radiation followed
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation followed by chemotherapy (sequential)
Study: 6198313
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with temporary interruption for radiation (sandwich)
Study: 29504498
Drug: High-dose inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose inhaled glucocorticoids (fluticasone at a dose of 220 μg per inhalation, two inhalations twice daily) for 7 days at early signs of loss of asthma control.
Study: 29504498
Drug: Low-dose inhaled
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose inhaled glucocorticoids (fluticasone propionate at a dose of 44 μg per inhalation, two inhalations twice daily) continued.
Study: 26474541
Drug: Implant sites
Normalized name: PAD,BITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant sites with <2 mm of keratinized mucosa (Narrow Group)
Study: 26474541
Drug: Implant sites
Normalized name: PAD,BITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant sites with ≥2 mm of keratinized mucosa (Wide Group)
Study: 15139955
Drug: Topical fluoride
Normalized name: Carles 60 Second APF 1.23% Topical Fluoride Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fluoride varnish (0.1 mg, Duraphat) for 6 h
Study: 9589293
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g mesalamine enema
Study: 9589293
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g mesalamine enema
Study: 9589293
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g mesalamine enema
Study: 2972628
Drug: Short interval
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short interval regimen (10 micrograms of Merck Sharp & Dohme recombinant HB vaccine at 0, 2, and 6 weeks)
Study: 23146293
Drug: ranolazine, 375
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranolazine, 375 mg bid for 3 weeks (group 1)
Study: 23146293
Drug: ranolazine, 375
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranolazine, 375 mg bid for 2 weeks, followed by placebo bid for 1 week (group 2)
Study: 19364687
Drug: Cholecalciferol (vitamin
Normalized name: cholecalciferol (vitamin D3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (vitamin D3) 50,000 units weekly for 8 weeks
Study: 19364687
Drug: Severely deficient
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severely deficient patients (25[OH]D <10 ng/mL) treated in an unblinded fashion
Study: 11095487
Drug: Conjugated estrogen
Normalized name: Conjugated estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogen (Premarin), 0.625 mg/day
Study: 11095487
Drug: Droloxifene, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droloxifene, 60 mg/day
Study: 11095487
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment for 4 weeks)
Study: 9050018
Drug: Noradrenaline (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline (i.v. infusion at doses of 10-160 ng/kg/min)
Study: 9050018
Drug: Noradrenaline (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline (i.v. infusion)
Study: 9050018
Drug: Tyramine (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyramine (i.v. infusion at doses of 5-20 micrograms/kg/min)
Study: 9050018
Drug: Tyramine (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyramine (i.v. infusion)
Study: 9050018
Drug: Atropine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (1.5 micrograms/kg i.v. loading dose followed by 0.15 microgram/kg/min i.v. infusion)
Study: 9050018
Drug: Doxazosin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (2 mg p.o.)
Study: 9050018
Drug: Yohimbine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (15 mg p.o.)
Study: 9050018
Drug: Bisoprolol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (15 mg p.o.)
Study: 28777054
Drug: Compression therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression therapy group (n = 20)
Study: 27087510
Drug: Analysis of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analysis of individual patterns of hCGβcf excretion
Study: 20637377
Drug: PCT strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCT strategy to treat all patients with PCT of 0.5 ng/mL or greater
Study: 11991610
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy (5 MU interferon-alpha2b daily for 4 weeks followed by 5 MU TIW for 44 weeks)
Study: 11991610
Drug: Noninduction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninduction therapy (5 MU interferon-alpha2b TIW for 48 weeks)
Study: 12814477
Drug: Noninduction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninduction therapy